Error loading player: No playable sources found

Coupling Mass Spectrometry (MS) with non-MS Assays for Automated Profiling of Antibody Impurities | Presented by Agilent Technologies

Date
January 30, 2025
This product is not available for individual purchase, but it is available as part of the following products:

Session Speaker:


Harsha GunawardenaJohnson & Johnson Innovative Medicine


Related Products

Thumbnail for Parallel Session 5B - Immunogenicity Risk and Control
Parallel Session 5B - Immunogenicity Risk and Control
Peptides, proteins and oligonucleotide are becoming essential medical treatments for many progressive, debilitating, or life-threatening diseases. However, the development of these potential therapies can be derailed by product immunogenicity as it can impact on safety and efficacy…
Thumbnail for Parallel Session 2B- LER 2025: Strategies Today for Overcoming Low Endotoxin Recovery
Parallel Session 2B- LER 2025: Strategies Today for Overcoming Low Endotoxin Recovery
Monitoring and control of endotoxin are critical aspects of an overall microbial control strategy necessary to ensure drug product quality and patient safety…
Thumbnail for Parallel Session 6B: The Critical Need to Protect the Horseshoe Crab: Initiatives from Industry, Suppliers and Regulators to Replace the LAL Assay
Parallel Session 6B: The Critical Need to Protect the Horseshoe Crab: Initiatives from Industry, Suppliers and Regulators to Replace the LAL Assay
The pharmaceutical industry is increasingly viewed as a key sector systemically important in reversing nature loss.     One of the sector’s key dependencies is on the horseshoe crab , a species that is vital to marine ecosystems only located in a few locations globally…
Thumbnail for Parallel Session 2A - Science vs the Fear Factor: Alternative Potency Assays for Recombinant Biologics and Vaccines
Parallel Session 2A - Science vs the Fear Factor: Alternative Potency Assays for Recombinant Biologics and Vaccines
Potency analytical control strategies are critical to support biopharmaceutical drug and vaccine development throughout the product lifecycle…